Search results for "Remission"

showing 10 items of 213 documents

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

2004

Abstract This phase 2 pilot study was conducted to determine the efficacy and safety of imatinib mesylate in patients with c-kit–positive acute myeloid leukemia (AML) refractory to or not eligible for chemotherapy. Twenty-one patients were enrolled and received imatinib 600 mg orally once daily. Five responses were seen primarily in patients, starting with relatively low blast counts in bone marrow (BM) and peripheral blood (PB): 2 patients who were considered refractory on chemotherapy on the basis of persistence of blasts in PB and BM met the criteria for complete hematologic remission, 1 patient had no evidence of leukemia, and 2 patients achieved a minor response. Treatment with imatini…

AdultMaleOncologymedicine.medical_specialtyAdolescentmedicine.medical_treatmentDNA Mutational AnalysisImmunologyAntineoplastic AgentsCell CountPilot ProjectsBiochemistryPiperazineshemic and lymphatic diseasesInternal medicineHumansMedicinePhosphorylationneoplasmsAgedSalvage TherapyChemotherapybusiness.industryRemission InductionMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseImmunohistochemistryClinical trialProto-Oncogene Proteins c-kitLeukemiaPyrimidinesTreatment OutcomeImatinib mesylatemedicine.anatomical_structureLeukemia MyeloidAcute DiseaseBenzamidesImmunologyImatinib MesylateImmunohistochemistryFemaleBone marrowBlast Crisisbusinessmedicine.drugBlood
researchProduct

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients…

2003

Patients with no prior chemotherapy and with advanced and progressive follicular lymphoma (FCL) or mantle cell lymphoma (MCL) were enrolled into a treatment protocol combining CHOP/rituximab-CHOP therapy with subsequent consolidation high-dose therapy (HDT) to evaluate the safety and feasibility of this treatment. Overall, 15 patients were enrolled and 13 patients completed the entire treatment protocol without major toxicities or increased infectious complications. One patient withdrew consent after achieving complete remission (CR) prior to HDT. One patient was taken off study with signs of disease progression after induction treatment. All patients showed stable engraftment after HDT. Re…

AdultMaleOncologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellCHOPTransplantation AutologousAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideImmunosuppression TherapyPeripheral Blood Stem Cell TransplantationTransplantationChemotherapybusiness.industryGraft SurvivalRemission InductionImmunityAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurvival AnalysisNon-Hodgkin's lymphomaSurgeryLymphomaTransplantationDoxorubicinVincristineFeasibility StudiesPrednisoneFemaleRadiotherapy AdjuvantMantle cell lymphomaRituximabRituximabbusinessmedicine.drugBone Marrow Transplantation
researchProduct

DNA measurements for monitoring chemotherapy in advanced head and neck carcinomas

1994

Background. Quantitative DNA measurements have demonstrated prognostic relevance in various malignancies, including head and neck cancer. The application of DNA measurements in monitoring and predicting the outcome of chemotherapy in treating patients with head and neck cancer was investigated. Methods. Twenty-five patients with advanced squamous cell carcinomas of the head and neck who underwent primary chemotherapy with three courses of cisplatin and 5-fluorouracil (5-FU) were examined in this study. Cytologic smears from the tumor site, as well as from normal mucosa, were taken before and 1 week after each course of chemotherapy. Quantitative DNA measurements were performed using an auto…

AdultMaleOncologymedicine.medical_specialtyPathologymedicine.medical_treatmentCellchemistry.chemical_compoundText miningCytologyInternal medicinemedicineHumansAgedCisplatinChemotherapybusiness.industryRemission InductionHead and neck cancerHistologyDNA NeoplasmMiddle AgedPrognosismedicine.diseaseTreatment Outcomemedicine.anatomical_structureOtorhinolaryngologychemistryHead and Neck NeoplasmsCarcinoma Squamous CellFemaleDrug MonitoringbusinessDNAmedicine.drugHead & Neck
researchProduct

Methotrexate, Vinblastine, Epidoxorubicin, and Bleomycin as Second-Line Chemotherapy for Recurrent and/or Metastatic Squamous Cell Carcinoma of the H…

1994

Thirty evaluable patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck region previously treated with cisplatin-based chemotherapy were treated with a combination of methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy. Besides surgery and/or radiotherapy all patients had previously received chemotherapy as induction therapy or as palliation for recurrent disease. Only 20% of patients achieved a partial objective response with a mean duration of 5.6 months (range 3.2-6.2), and 30% of patients had a stabilization of disease with a mean duration of 4.2+ months (range 3.8-6.0). Patients who responded had rhinopharyngeal carcinoma…

AdultMaleOncologymedicine.medical_specialtyVomitingmedicine.medical_treatmentVinblastineBleomycinSecond line chemotherapyMetastasisBleomycinchemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansBasal cellHead and neckAgedEpirubicinCisplatinStomatitisChemotherapybusiness.industryPalliative CareRemission InductionHead and neck cancerLeukopeniaMiddle Agedmedicine.diseaseCombined Modality TherapySurvival RateMethotrexateOtorhinolaryngologychemistryHead and Neck NeoplasmsCarcinoma Squamous CellFemaleFluorouracilCisplatinNeoplasm Recurrence Localbusinessmedicine.drugORL
researchProduct

Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remissio…

2019

Despite being recommended for use in clinical trials, the consensus remission criteria were found to leave patients with persisting symptoms, relevant areas of functional impairment and a decreased sense of wellbeing. Therefore, to evaluate the appropriateness of the schizophrenia consensus criteria, a definition of remission based on the Clinical Global Impression Scale (CGI) was developed and remitter subgroups were compared.239 patients with a schizophrenia spectrum disorder were evaluated regarding their remission status after inpatient treatment. Remission in schizophrenia was defined according to the symptom-severity component of the consensus criteria by Andreasen et al. and a CGI ba…

AdultMalePediatricsmedicine.medical_specialtyConsensusMedizinConsensus criteriaSeverity of Illness IndexAsymptomaticYoung Adult03 medical and health sciences0302 clinical medicineRemission criteriaOutcome Assessment Health Caremental disordersmedicineHumansBiological PsychiatryDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryRemission InductionMiddle Agedmedicine.disease030227 psychiatry3. Good healthClinical trialPsychiatry and Mental healthSchizophreniaSchizophreniaClinical Global ImpressionFemalemedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia spectrum
researchProduct

Pancreatic encephalopathy: a 7-year follow-up case report and review of the literature

2003

Pancreatic encephalopathy is a rare complication of acute pancreatitis. Clinical features include focal neurological signs and acute onset of dementia. This picture can fluctuate over time: cyclic progression with remission and relapses has been described. We present the case of a 43-year-old man who, after an acute episode of pancreatitis, experienced five relapses, with alternating focal signs. The patient has improved, but cognitive impairment persists after a 7-year follow-up.

AdultMalePediatricsmedicine.medical_specialtyNeurologyRemission SpontaneousEncephalopathyDermatologyNeuropsychological TestsDiagnosis DifferentialRecurrencemedicineHumansDementiaNeuroradiologyBrain Diseasesbusiness.industryElectrodiagnosisGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingSurgeryParesisPsychiatry and Mental healthPancreatitisAcute DiseaseAmylasesChronic DiseaseDisease ProgressionAcute pancreatitisPancreatitisAtaxiaNeurology (clinical)NeurosurgeryCognition DisordersComplicationbusinessFollow-Up StudiesNeurological Sciences
researchProduct

Liebowitz Social Anxiety Scale (LSAS): Optimal cut points for remission and response in a German sample

2017

The Liebowitz Social Anxiety Scale (LSAS) is the most frequently used instrument to assess social anxiety disorder (SAD) in clinical research and practice. Both a self-reported (LSAS-SR) and a clinician-administered (LSAS-CA) version are available. The aim of the present study was to define optimal cut-off (OC) scores for remission and response to treatment for the LSAS in a German sample. Data of N = 311 patients with SAD were used who had completed psychotherapeutic treatment within a multicentre randomized controlled trial. Diagnosis of SAD and reduction in symptom severity according to the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th editi…

AdultMalePsychometricsLiebowitz social anxiety scaleSensitivity and Specificitylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanyHumansPsychiatric Status Rating ScalesReceiver operating characteristicRemission InductionSocial anxietyNonparametric statisticsReproducibility of ResultsPhobia SocialGold standard (test)030227 psychiatryPsychotherapyClinical PsychologyTreatment OutcomeClinical researchFemalePsychology030217 neurology & neurosurgeryCut-pointClinical psychologyClinical Psychology & Psychotherapy
researchProduct

Monitoring changes in anti-tuberculosis treatment: associated factors determined at the time of diagnosis

2013

OBJECTIVES: To determine predictive factors for changes in standard anti-tuberculosis chemotherapy at the time of diagnosis. METHODS: A prospective study was performed among tuberculosis (TB) patients treated at specialised centres during 2008-2009. Treatment outcome was monitored per standard guidelines. Treatment was considered successful if the patient was cured or completed treatment. Factors associated with treatment modification were analysed at the bivariate and multivariate levels using logistic regression. RESULTS: A total of 427 patients were included in the study. The initial standard treatment regimen was retained for 249 patients (58.3%), extended to 9 months for 36 (8.4%) and …

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyTime FactorsMultivariate analysisTuberculosisAntitubercular AgentsComorbiditySex FactorsDrug Resistance Multiple BacterialTuberculosis Multidrug-ResistantOdds RatioHumansTuberculosisMedicineProspective StudiesProspective cohort studyDrug Substitutionbusiness.industryStandard treatmentRemission InductionAge FactorsOdds ratioMiddle Agedmedicine.diseaseComorbidityRegimenLogistic ModelsTreatment OutcomeInfectious DiseasesSpainMultivariate AnalysisPractice Guidelines as TopicSputumDrug Therapy CombinationFemaleGuideline Adherencesense organsmedicine.symptombusinessThe International Journal of Tuberculosis and Lung Disease
researchProduct

Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA tr…

2019

Background: In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA). Aims: To evaluate health-related quality of life (HRQoL) in APPRECIA trial. Methods: HRQoL was evaluated using disease-specific shortened Spanish version of the IBDQ (SIBDQ-9) and generic European Quality of Life-5 Dimensions (EQ-5D) questionnaires, completed at baseline and at weeks 24 and 52. Results: Sixty-one patients (37 ADA and 24 AZA) had evaluable data for HRQoL. Patients treated with ADA or AZA had significant improvement from baseline to weeks 24 and 52 in SIBDQ-9 and EQ-5D (p < 0.001 and p = 0.006 for all comparisons…

AdultMaleQuality of lifemedicine.medical_specialtyPostoperative therapyAzathioprinePostoperative recurrence03 medical and health sciences0302 clinical medicineCrohn DiseaseQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAzathioprineAdalimumabHumansMedicineIn patientPostoperative PeriodCrohn's diseaseHepatologybusiness.industryRemission InductionGastroenterologyAdalimumabSpanish versionProphylactic drug therapymedicine.diseaseEndoscopes GastrointestinalCrohn's diseaseSpain030220 oncology & carcinogenesisQuality of LifeFemale030211 gastroenterology & hepatologyIntestinal resectionbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

2002

The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or autologous SCT and underwent a salvage NST. 18/22 patients (82%) engrafted after NST. 13/16 patients (81%) with active disease reached complete remission (CR). 11 of 13 patients developed GVHD. After first NST 10/11 patients (91%) engrafted. Six of seven patients with active disease reached CR. Three of five relapsing patients reached subsequent CR after donor lymphocyte infusions, termination of immun…

AdultMaleRiskMelphalanCancer Researchmedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentSalvage therapyGraft vs Leukemia EffectPilot ProjectsAcute lymphocytic leukemiamedicineHumansPhiladelphia ChromosomeSurvival rateSalvage TherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationImmunosuppressionHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryFludarabineSurvival RateTransplantationsurgical procedures operativeOncologyDisease ProgressionFeasibility StudiesFemalebusinessmedicine.drugLeukemia
researchProduct